ストックスクリーナーアプリを入手
2.42
0.41%
0.010
アフターアワーズ：
2.42
前日終値:
$2.41
開ける：
$2.42
24時間の取引高:
190.32K
Relative Volume:
1.17
時価総額：
$2.91M
収益：
-
当期純損益:
$-4.74M
株価収益率:
-3.7369
EPS:
-0.6476
ネットキャッシュフロー:
$-3.46M
1週間 パフォーマンス:
-3.97%
1か月 パフォーマンス:
-38.21%
6か月 パフォーマンス:
-58.46%
1年 パフォーマンス:
-73.70%
1日の値動き範囲:
$2.4001
$2.75
1週間の範囲:
$2.21
$2.75
52週間の値動き範囲:
$2.21
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
名前
Lipella Pharmaceuticals Inc
セクター
電話
412-901-0315
住所
400 N LEXINGTON ST, PITTSBURGH
LIPO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LIPO | 2.42 | 2.91M | 0 | -4.74M | -3.46M | -0.6476 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lipella Pharmaceuticals Inc (LIPO) 最新ニュース
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - TipRanks
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Expion360 Inc’s latest rating changes from various analysts - Knox Daily
Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily
The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News
Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar
Lipella reports positive phase 2a trial results for OLP treatment - Investing.com
Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan
A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Lipella stock soars 200% on Phase 2 study initiation - MSN
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Lipella Pharmaceuticals Inc (LIPO) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):